InMode has reported preliminary Q2 2026 revenue guidance of $95.2M–$95.4M, exceeding analyst expectations and reiterating full-year 2026 revenue guidance of $365M–$375M. The beat occurs against the backdrop of the unsolicited Steel Partners takeover bid, suggesting underlying demand strength for the company's monopolar RF and fractional ablative platforms.
Business & M&A
InMode Guides Q2 Revenue to $95.2M–$95.4M, Reiterates $365M–$375M FY 2026 Target
Device maker's preliminary results beat expectations amid takeover contest.
1-YEAR MOVE
INMD
▲1.0%
| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
InMode's Q2 beat and $365M–$375M FY guidance underscore strong RF demand, even as takeover contest unfolds.
The revenue trajectory reflects sustained adoption of Morpheus8 and related systems across independent medspas, dermatology practices, and plastic surgery centers. For practice owners, the key takeaway is InMode's market momentum—and the uncertainty a contested acquisition introduces. Equipment pricing, rebate structures, and financing terms could shift materially depending on which bidder prevails. The company reports full results August 5.
Source: original report ↗
Frequently asked questions
What is InMode's Q2 2026 revenue guidance?
InMode guided Q2 2026 revenue to $95.2M–$95.4M, beating analyst expectations. The company maintained its full-year 2026 revenue guidance of $365M–$375M, signaling confidence in sustained demand for its RF and ablative platforms.
Which InMode devices are driving revenue growth in medspas?
Morpheus8 and related monopolar RF and fractional ablative systems are the primary drivers of adoption across independent medspas, dermatology practices, and plastic surgery centers. These platforms continue to see strong uptake in the aesthetic market.
How could the Steel Partners takeover bid affect InMode equipment pricing?
Equipment pricing, rebate structures, and financing terms could shift materially depending on which bidder prevails in the contested acquisition. Practice owners should monitor the takeover outcome, as it may impact equipment costs and payment options.
When will InMode report full Q2 2026 results?
InMode will report full Q2 2026 results on August 5. The preliminary guidance of $95.2M–$95.4M was released ahead of the complete earnings announcement.
Is InMode's revenue growth sustainable amid the takeover contest?
InMode's Q2 beat and maintained full-year guidance suggest underlying demand strength despite the unsolicited takeover bid. The company's market momentum across medspas and surgical practices indicates sustained adoption, though acquisition uncertainty could affect future strategy and pricing.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.